ADVANCE PURCHASE AGREEMENT FOR SARS-CoV-2/COVID-19 VACCINE

Official notice

Authority: Business Energy and Industrial Strategy

GoodsAward procedure without prior publication of a call for competition

Sectors: Medical Devices & Pharma (33) Delivery: Belgium (BE)

Awarded value£1published contract · exc. VAT

Awarded 15 Jan 2021no call for competition

Awarded to JANSSEN PHARMACEUTICA NV

What is being bought

Published requirement description

Procurement of Janssen's vaccine candidate Ad26.COV2-S.

CPV: Vaccines

The lotProcurement structure

single lot · no lot value published

Lot #1This contract has been procured using the negotiated procedure without prior…Awarded

This contract has been procured using the negotiated procedure without prior publication under regulation 32 of the Public Contracts Regulations 2015 on the basis that the award of the contract to Janssen is strictly necessary for unforeseeable reasons of extreme urgency; i.e. the urgent requirement to secure priority access to a viable vaccine to end the Covid-19 pandemic (Regulation 32(2)(c)). Additional information: Information on contract value is being withheld due to commercial sensitivity under Regulation 50(6)(b) and (c) as the publication of the price may enable competitors to calculate cost per dose. This will (i) commercially prejudice the supplier in its ongoing negotiations with other national governments; (ii) commercially prejudice the contracting authority in its ongoing negotiations with other vaccine vendors and (iii) impact fair competition between vaccine vendors.

Delivery listed: Belgium (BE)

Procedure terms & legal framework

From the official record

Procedure method: Award procedure without prior publication of a call for competition
Legal basis: CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
Procurement category: Goods
Notice status: Awarded without competition
Procurement threshold: Unspecified in notice
Regulatory regime: Standard
Commercial structure: Stand-alone contract (no framework)
Competition type: Direct award (no call for competition)
GPA / WTO covered: Yes (GPA)
Recurring procurement: Unspecified in notice
First published: 12 Feb 2021, 17:45 GMT
Last source update: 12 Feb 2021, 17:45 GMT
Authority reference: 4846/01/2021
FTS notice number: 2021/S 000-002970
Classification (CPV): Vaccines
Delivery area: Belgium (BE)
Official registry OCID: ocds-h6vhtk-029301 Find a Tender

Why no open competition: Extreme urgency brought about by events unforeseeable for the contracting authority/entity and in accordance with the strict conditions stated in the directive
Published justification: The award of the contract to Janssen is strictly necessary for unforeseeable reasons of extreme urgency; i.e. the urgent requirement to find a viable vaccine to end the Covid 19 pandemic (Regulation 32(2)(c)).

Commercial outcome & contract awards

Published awards, contracts and bid statistics, not a forecast

Awards 1

Awarded value £11 contract exc. VAT

Bids received 1

Contracts signed 1latest 15 Jan 2021

Awarded to	Value	Date	Status
JANSSEN PHARMACEUTICA NV	£1 †	—	Awarded

Contracts

ADVANCE PURCHASE AGREEMENT FOR SARS-CoV-2/COVID-19 VACCINE · JANSSEN PHARMACEUTICA NV
Signed
15 Jan 2021
Value
£1
Status
active

Bid statistics published by the authority

Bids	SME	VCSE	Valid bid range
1bids	—	—	—

Contracting authority & participating public bodies

Business Energy and Industrial Strategy

Contracting authorityMinistry or any other national or federal authority, including their regional or local subdivisionsGeneral public services 1 Victoria Street, London, UK, SW1H0ETContact email

Dispute resolution & review bodies

Department of Business, Energy and Industrial StrategyReview body London

Bidders & participating suppliers

1 commercial party on the notice

JANSSEN PHARMACEUTICA NVAwarded supplier 30 Turnhoutseweg, Beerse, BE, B-2340

Official documents & specifications

Official links; attachments are not copied

No document links were published on the notice.